Recombinant Human IFN-alpha I/IFN17 Protein, CF

Catalog #: 11082-IF Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11082-IF-050

Recombinant Human IFN‑ alpha 1 Protein Bioactivity.

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IFN-alpha I/IFN17 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED₅₀ for this effect is 1.00-20.0 pg/mL.

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha I protein
Cys24-Asp189

Accession #

P01571.2

N-terminal Sequence
Analysis

Cys24

Predicted Molecular Mass

19 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Product Datasheets

11082-IF

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11082-IF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human IFN-alpha1 Protein (Catalog # 11082-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED₅₀ for this effect is 1.00-20.0 pg/mL

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human IFN‑ alpha 1 Protein (Catalog # 11082-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18‑22 kDa.

Reconstitution Calculator

Background: IFN-alpha I

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical‑bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). There is not a mouse homolog for IFNA17, but mature human IFNA17 shares 58% aa sequence identity with chimpanzee IFNA17. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection (8). IFNA17 has been shown to be potent against HIV-1 activity (9). Human IFNA17 is the only IFNA subtype identified with antiviral activity but a reduced ability to activate NK cells (10). A mutation in IFNA17, Ile184Arg, is associated with an increased risk for cervical cancer (11).

References

Pestka S, et al. (1987) Annu Rev Biochem. 56:727.
Goeddel, D.V. et al. (1980) Nature 287:411.
Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
Wittling, M.C. et al. (2021) Front Immunol. 11:605673.
van Pesch, V. et al. (2004) J. Virol. 78:8219.
James C.M. et al. (2007) Vaccine. 25(10):1856.
Moll, H.P. et al. (2011) Cytokine. 53:52.
Lavender, K.J. et al. (2016) J Virol. 90:6001.
Ortaldo, J.R. et al. (1984) PNAS 81:4926.
Kim, J.W. et al. (2003) Cancer Lett. 189:183.

Long Name

Interferon alpha I

Entrez Gene IDs

3451 (Human)

Alternate Names

IFNA; IFNA17; IFNalpha I; IFN-alpha I; IFN-alpha-17; IFN-alphaI; INFA; interferon alpha-17; Interferon alpha-88; Interferon alpha-I'; Interferon alpha-T; interferon alpha-WA; interferon, alpha 17; LeIF I; LEIF2C1